These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 17593239

  • 1. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K, Finer N, Rössner S.
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [Abstract] [Full Text] [Related]

  • 2. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS.
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
    [Abstract] [Full Text] [Related]

  • 3. Orlistat and sibutramine beyond weight loss.
    Mannucci E, Dicembrini I, Rotella F, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [Abstract] [Full Text] [Related]

  • 4. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 5. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 6. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007 Nov; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 8. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH, Fernstrom JD.
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [Abstract] [Full Text] [Related]

  • 9. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M.
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [Abstract] [Full Text] [Related]

  • 10. Sibutramine treatment in obesity: predictors of weight loss including rorschach personality data.
    Elfhag K, Rössner S, Carlsson AM, Barkeling B.
    Obes Res; 2003 Nov; 11(11):1391-9. PubMed ID: 14627761
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, Zanella MT, Coutinho W.
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [Abstract] [Full Text] [Related]

  • 12. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial.
    Svendsen M, Rissanen A, Richelsen B, Rössner S, Hansson F, Tonstad S.
    Obesity (Silver Spring); 2008 Feb; 16(2):327-33. PubMed ID: 18239640
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 14. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G, Romano C, De Caprio C, Contaldo F, Salanitri T, di Luzio Paparatti U, Pasanisi F.
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [Abstract] [Full Text] [Related]

  • 15. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
    Kaya A, Aydin N, Topsever P, Filiz M, Oztürk A, Dağar A, Kilinç E, Ekmekcioglu C.
    Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
    [Abstract] [Full Text] [Related]

  • 17. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ, Wilton LV, Shakir SA.
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [Abstract] [Full Text] [Related]

  • 18. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ, Ernest P.
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [Abstract] [Full Text] [Related]

  • 19. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL, Apovian CM, Aronne LJ, Fernstrom MH, Frank A, Greenway FL, Heber D, Kushner RF, Cwik KM, Walch JK, Hewkin AC, Blakesley V.
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [Abstract] [Full Text] [Related]

  • 20. Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood.
    Elfhag K, Rössner S, Barkeling B, Rooth P.
    Pharmacol Res; 2005 Feb; 51(2):159-63. PubMed ID: 15629262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.